GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: BAY 2927088 | BAY-2927088 | BAY2927088 | Example 2 [WO2020216781]
Compound class:
Synthetic organic
Comment: Sevabertinib is the INN for an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antineoplastic potential. The chemical structure was obtained from WHO proposed INN list 131 (August 2024). It is one of the compounds claimed in patent WO2020216781A1 [1]. Bayer are one of the patent assignees, and they have an EGFR/ERBB2 inhibitor in early clinical development (BAY 2927088), with online resources confirming the INN-company code association.
In September 2025, the FDA issued Priority Review to expedite sevabertinib's route to clinical approval. |
|
References |
1. Siegel S, Siegel F, Schulze V, Berger M, Graham K, Sülzle D, Bömer U, Korr D, Schröder J, Mönning U et al.. (2020)
4h-pyrrolo[3,2-c]pyridin-4-one compounds. Patent number: WO2020216781A1. Assignee: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.. Priority date: 22/04/2020. Publication date: 29/10/2020. |